MA33291B1 - Pipéridines substituées - Google Patents

Pipéridines substituées

Info

Publication number
MA33291B1
MA33291B1 MA34376A MA34376A MA33291B1 MA 33291 B1 MA33291 B1 MA 33291B1 MA 34376 A MA34376 A MA 34376A MA 34376 A MA34376 A MA 34376A MA 33291 B1 MA33291 B1 MA 33291B1
Authority
MA
Morocco
Prior art keywords
diseases
substituted piperidines
treating
preventing
piperidines
Prior art date
Application number
MA34376A
Other languages
English (en)
Inventor
Dirk Heimbach
Susanne Roehrig
Grande Yolanda Cancho
Eckhard Bender
Katja Zimmermann
Anja Buchmueller
Christoph Gerdes
Mark Jean Gnoth
Kersten Matthias Gericke
Mario Jeske
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA33291B1 publication Critical patent/MA33291B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouvelles pipéridines substituées, des procédés pour les produire, leur utilisation pour traiter et/ou prévenir des maladies, ainsi que leur utilisation pour produire des médicaments pour traiter et/ou prévenir des maladies, en particulier des maladies cardiovasculaires et des maladies tumorales.
MA34376A 2009-05-27 2010-05-18 Pipéridines substituées MA33291B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009022894A DE102009022894A1 (de) 2009-05-27 2009-05-27 Substituierte Piperidine
PCT/EP2010/003024 WO2010136138A1 (fr) 2009-05-27 2010-05-18 Pipéridines substituées

Publications (1)

Publication Number Publication Date
MA33291B1 true MA33291B1 (fr) 2012-05-02

Family

ID=42537882

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34376A MA33291B1 (fr) 2009-05-27 2010-05-18 Pipéridines substituées

Country Status (29)

Country Link
US (3) US8440657B2 (fr)
EP (1) EP2435431A1 (fr)
JP (1) JP5728687B2 (fr)
KR (1) KR20120024652A (fr)
CN (1) CN102482270B (fr)
AR (1) AR076709A1 (fr)
AU (1) AU2010252339B2 (fr)
BR (1) BRPI1012775A2 (fr)
CA (1) CA2763386A1 (fr)
CO (1) CO6470822A2 (fr)
CR (1) CR20110627A (fr)
CU (1) CU24011B1 (fr)
DE (1) DE102009022894A1 (fr)
EA (1) EA021944B1 (fr)
HK (1) HK1171450A1 (fr)
HN (1) HN2011003102A (fr)
IL (1) IL215903A0 (fr)
MA (1) MA33291B1 (fr)
MX (1) MX2011012507A (fr)
MY (1) MY166555A (fr)
NZ (1) NZ596621A (fr)
PE (1) PE20120402A1 (fr)
SG (1) SG175759A1 (fr)
TN (1) TN2011000596A1 (fr)
TW (1) TWI464166B (fr)
UA (1) UA107576C2 (fr)
UY (1) UY32652A (fr)
WO (1) WO2010136138A1 (fr)
ZA (1) ZA201108609B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
BR112014007257B1 (pt) 2011-10-07 2023-04-25 Takeda Pharmaceutical Company Limited Composto 1-arilcarbonil-4-oxi-piperidina
JP5900182B2 (ja) * 2012-06-21 2016-04-06 セントラル硝子株式会社 α，α−ジフルオロ芳香族化合物の製造方法
JP6197348B2 (ja) * 2013-04-25 2017-09-20 セントラル硝子株式会社 α，α−ジフルオロ芳香族化合物の保存安定性の向上方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO1997036873A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines et hexahydro-1h-azepines declenchant la liberation de l'hormone de croissance
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
ATE345799T1 (de) 2001-10-15 2006-12-15 Janssen Pharmaceutica Nv Substituierte 4-phenyl-4-(1h-imidazol-2-yl)- piperidinderivate zur verringerung von ischämischer schädigung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
WO2006002349A1 (fr) 2004-06-24 2006-01-05 Incyte Corporation Composes amido et leur utilisation comme produits pharmaceutiques
MXPA06014574A (es) * 2004-06-24 2007-03-12 Incyte Corp Piperidinas n-sustituidas y su uso como farmaceuticos.
JP2008504279A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
EA200700251A1 (ru) 2004-08-10 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве фармацевтических средств
DE102004042607A1 (de) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
EP1705960A1 (fr) 2005-03-21 2006-09-27 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Lampe électroluminescente
CA2621255A1 (fr) 2005-09-21 2007-04-05 Incyte Corporation Utilisation pharmaceutique de composes amido
WO2007089683A1 (fr) 2006-01-31 2007-08-09 Incyte Corporation Composés amido et leur utilisation comme produits pharmaceutiques
TW200808807A (en) 2006-03-02 2008-02-16 Incyte Corp Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007130898A1 (fr) 2006-05-01 2007-11-15 Incyte Corporation URÉES TÉTRASUBSTITUÉES MODULATEURS DE LA 11-β HYDROXYL STÉROÏD DÉSHYDROGÉNASE DE TYPE 1
DK2227466T3 (da) * 2007-11-30 2011-08-08 Bayer Schering Pharma Ag Heteroaryl-substituerede piperidiner
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022892A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022897A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022895A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine

Also Published As

Publication number Publication date
US20120135985A1 (en) 2012-05-31
JP5728687B2 (ja) 2015-06-03
NZ596621A (en) 2013-12-20
HN2011003102A (es) 2015-02-23
IL215903A0 (en) 2012-01-31
EP2435431A1 (fr) 2012-04-04
US8440657B2 (en) 2013-05-14
EA201190313A1 (ru) 2012-05-30
UA107576C2 (ru) 2015-01-26
AR076709A1 (es) 2011-06-29
CA2763386A1 (fr) 2010-12-02
HK1171450A1 (en) 2013-03-28
AU2010252339A1 (en) 2011-12-08
JP2012528089A (ja) 2012-11-12
ZA201108609B (en) 2013-02-27
EA021944B1 (ru) 2015-10-30
CN102482270A (zh) 2012-05-30
CO6470822A2 (es) 2012-06-29
KR20120024652A (ko) 2012-03-14
MX2011012507A (es) 2011-12-14
UY32652A (es) 2010-12-31
TWI464166B (zh) 2014-12-11
MY166555A (en) 2018-07-16
CU20110214A7 (es) 2012-03-15
US8202862B2 (en) 2012-06-19
DE102009022894A1 (de) 2010-12-02
US20130252948A1 (en) 2013-09-26
SG175759A1 (en) 2011-12-29
US20100305111A1 (en) 2010-12-02
AU2010252339B2 (en) 2014-10-23
CR20110627A (es) 2012-03-22
BRPI1012775A2 (pt) 2019-09-24
WO2010136138A1 (fr) 2010-12-02
TN2011000596A1 (en) 2013-05-24
TW201107319A (en) 2011-03-01
CN102482270B (zh) 2015-02-25
CU24011B1 (es) 2014-06-27
PE20120402A1 (es) 2012-04-18

Similar Documents

Publication Publication Date Title
MA33290B1 (fr) Pipéridines substituées
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MY173616A (en) Compositions and methods for lowering triglycerides
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX337933B (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
MY159375A (en) Combinatorial therapy
MY151191A (en) Novel antibodies
MY161909A (en) Anti-her3 antibodies and uses thereof
WO2009068214A3 (fr) Pipéridines à substitution hétéroaryl
IN2012DN02737A (fr)
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
EA201001639A1 (ru) Композиции и способы их получения и применения
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MX2009004108A (es) Compuestos de tetrahidropirrolopiracina sustituidos teniendo afinidad al canal kcnq2/3 k+ y su uso en farmacos.
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MA33291B1 (fr) Pipéridines substituées
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
WO2009115252A3 (fr) Pyrazolamides substitués et leur utilisation
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
MX2012000572A (es) Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos.